

- (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. *Drug Des Dev Ther* 2015;9:4479-99.
12. Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, et al. Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. *Hum Gene Ther* 2019;30:446-58.
 13. Zhu X, Prasad S, Gaedicke S, Hettich M, Firat E, Niedermann G. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. *Oncotarget* 2015;6:171-84.
 14. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. *Mol Ther* 2010;18:843-51.
 15. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. *Nature* 1997;390:465-71.
 16. Yoon JH, Jung SM, Park SH, Kato M, Yamashita T, Lee IK, et al. Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes. *EMBO Mol Med* 2013;5:1720-39.
 17. Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. *Oncotarget* 2015;6:21614-27.
 18. Zhang Q, Hou X, Evans BJ, VanBlaricom JL, Weroha SJ, Cliby WA. LY2157299 monohydrate, a TGF-betaR1 inhibitor, suppresses tumor growth and ascites development in ovarian cancer. *Cancers (Basel)* 2018 7;10:260.
 19. Bureta C, Setoguchi T, Saitoh Y, Tominaga H, Maeda S, Nagano S, et al. TGF-beta promotes the proliferation of microglia in vitro. *Brain Sci* 2019;10:20.
 20. Liu FL, Mo EP, Yang L, Du J, Wang HS, Zhang J, et al. Autophagy is involved in TGF-beta1-induced protective mechanisms and formation of cancer-associated fibroblasts phenotype in tumor microenvironment. *Oncotarget* 2016;7:4122-41.
 21. Trapani JA. The dual adverse effects of TGF-beta secretion on tumor progression. *Cancer Cell* 2005;8:449-50.
 22. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. *Cancer Cell* 2005;8:369-80.
 23. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. *Annu Rev Immunol* 2002;20:323-70.
 24. McKarns SC, Schwartz RH, Kaminski NE. Smad3 is essential for TGF-beta 1 to suppress IL-2 production and TCR-induced proliferation, but not IL-2-induced proliferation. *J Immunol* 2004;172:4275-84.
 25. Janas ML, Groves P, Kienzle N, Kelso A. IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation. *J Immunol* 2005;175:8003-10.
 26. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von Boehmer H, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. *Proc Natl Acad Sci USA* 2005;102:419-24.
 27. Company ELA. A study of Galunisertib in participants with myelodysplastic syndromes. Available from: <https://clinicaltrials.gov/ct2/show/NCT02008318?term=NCT02008318&draw=2&rank=1>.
 28. Company ELA. A study in metastatic cancer and advanced or metastatic unresectable pancreatic cancer. Available from: <https://clinicaltrials.gov/ct2/show/NCT01373164?term=NCT01373164&draw=2&rank=1>.
 29. Company ELA. A study in recurrent glioblastoma (GB). Available from: <https://clinicaltrials.gov/ct2/show/NCT01582269?term=NCT01582269&draw=2&rank=1>.
 30. Company ELA. A study of LY2157299 in participants with hepatocellular carcinoma. Available from: <https://clinicaltrials.gov/ct2/show/NCT01246986?term=NCT01246986&draw=2&rank=1>.
 31. Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, et al. Targeting the TGFbeta pathway for cancer therapy. *Pharmacother* 2015;147:22-31.
 32. Company ELA. A study of Galunisertib (LY2157299) in combination with Nivolumab in advanced refractory solid tumors and in recurrent or refractory NSCLC, or hepatocellular carcinoma. Available from: <https://clinicaltrials.gov/ct2/show/NCT02423343?term=NCT02423343&draw=1&rank=1>.
 33. Company ELA. A study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in participants with metastatic pancreatic cancer. Available from: <https://clinicaltrials.gov/ct2/show/NCT02734160?term=NCT02734160&draw=2&rank=1>.
 34. Hou AJ, Chang ZL, Lorenzini MH, Zah E, Chen YY. TGF-beta-responsive CAR-T cells promote anti-tumor immune function. *Bioeng Transl Med* 2018;3:75-86.

Received for publication: 15 March 2020. Accepted for publication: 11 April 2020.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2020

Licensee PAGEPress, Italy

European Journal of Histochemistry 2020; 64(s2):3122

doi:10.4081/ejh.2020.3122